1 Fundación Clínica, Médica Sur. Puente de piedra 150, Col Toriello Guerra, 14050 Mexico City, Mexico ; 2 Translational Research Laboratory, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, 08916 Barcelona, Spain ; 3 Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, 08028 Barcelona, Spain.
Transl Lung Cancer Res. 2016 Feb;5(1):26-38. doi: 10.3978/j.issn.2218-6751.2016.01.13.
Small cell lung cancer (SCLC) represents between 13% and 15% of all diagnosed lung cancers worldwide. It is an aggressive neoplasia, with a 5-year mortality of 90% or more. It has historically been classified as limited disease (LD) and extensive disease (ED) in most study protocols. The cornerstone of treatment for any stage of SCLC is etoposide-platinum based chemotherapy; in limited stage (LS), concomitant radiotherapy to thorax and mediastinum. Prophylactic radiotherapy to the central nervous system (CNS) [prophylactic cerebral irradiation (PCI)] has diminished the incidence of brain metastasis as the site for relapse in LD and ED patients, therefore it should be offered to patients with complete response to induction first-line treatment. Regarding second-line treatment, results are more modest and topotecan is accepted as treatment for this scenario offering a modest benefit.
小细胞肺癌（SCLC）约占全球所有确诊肺癌的 13%至 15%。它是一种侵袭性肿瘤，5 年死亡率超过 90%。在大多数研究方案中，它通常被分为局限期（LD）和广泛期（ED）。SCLC 各期的治疗基石均为依托泊苷联合铂类化疗；局限期还需联合胸部和纵隔放疗。预防性脑照射（PCI）降低了 LD 和 ED 患者脑转移的发生率，因此应给予一线诱导治疗完全缓解的患者。对于二线治疗，疗效较为有限，拓扑替康是二线治疗的标准方案，能带来一定获益。
